Collaborations

Prof. Zimmer holds a chair in neuropharmacology at the Université Claude Bernard Lyon 1 and leads the brain imaging laboratory within the CERMEP-Imaging platform at the University Hospital of Lyon. He is expert in the development of serotonergic PET radiotracers.

Collaboration: development of novel serotonin 5-HT1A receptor PET radiotracers

https://www.linkedin.com/pub/luc-zimmer/57/230/b32

Lyon University, Lyon, France

Dr. Prickaers leads a research group focusing on signal transduction and plasticity in affective disorders and cognitive processes. He has previously conducted drug discovery programs in a pharmaceutical industry context.

Collaboration: procognitive activity of serotonin 5-HT1A receptor ‘biased’ agonists.

T1A

http://mhens.unimaas.nl/pag_staff.php?ID=1059&item=267

Université de Maastricht, Pays Bas

Prof. Leonardo leads a research team focusing on how temporal factors and genetic risk impact the expression of mental illness. He is an expert on the role of serotonin 5-HT1A receptor in regulating vulnerability to stress and depressive states.

Collaboration: influence of serotonin 5-HT1A receptor ‘biased’ agonists on anxiety and depression.

http://asp.cumc.columbia.edu/facdb/profile_list.asp?uni=el367&DepAffil=Psychiatry

Université de Columbia, New York City, Etats Unis

Dr Abdala Sheik is an expert on the neural circuits involved in generating respiratory rhythm, sympathetic activity and blood pressure. In particular, her work has advanced understanding of 5-HT1A receptors in Rett syndrome.

Collaboration: action of serotonin 5-HT1A agonists in transgenic mouse models of Rett syndrome

https://www.linkedin.com/pub/ana-paula-abdala-sheikh/98/484/94b

Université de Bristol, Royaume Uni

Prof. Anna Wesołowska is an expert behavioral pharmacologist, particularly in the area of serotonergic receptors. She has a wide experience in investigating the role of 5-HT receptor subtypes as well as in identification of novel serotonergic ligands.

Collaboration: drug discovery of novel chemical entities targeting mood deficits and psychosis.

 

http://www.uj.edu.pl/en_GB/

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: